A new review of preclinical studies suggests GLP-1 drugs like Ozempic may reduce key proteins linked to Alzheimer’s disease.

The FDA has approved Auvelity for treating agitation in patients with dementia due to Alzheimer’s disease, Axsome ...

Researchers at UC San Diego say they recently uncovered new insights into a protein that has emerged as a potential molecular “switch” that may determine whether Alzheimer’s-like brain changes lead to ...

Researchers at the Indiana University School of Medicine have developed a new way to read the brain's "energy network ...

The Food and Drug Administration (FDA) approved the drug Auvelity this week for the treatment of agitation in adults with ...

New research from Mayo Clinic shows that subtle biological changes may begin years before Alzheimer's symptoms appear.

Oral NMDA receptor antagonist gets an expanded indication ...

Subtle biological changes linked to Alzheimer's disease may begin as early as the late 50s—decades before memory loss or ...

Care at home often lacks the clinical leadership and structure necessary to be safe, consistent, and sustainable.

The sub-study examined the impact of the therapy on prespecified Alzheimer’s plasma biomarkers in the subjects. Credit: ...

Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease May 1, 2026 8:00 ...

Alzheimer’s disease agitation could mean peak sales of over $2.1 billion for Axsome’s Auvelity, according to analysts at ...